{"id":1068265,"date":"2022-12-08T00:13:55","date_gmt":"2022-12-08T05:13:55","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/design-therapeutics-reports-positive-data-from-single-ascending-dose-trial-of-dt-216-for-the-treatment-of-friedreich-ataxia-and-portfolio-progress\/"},"modified":"2024-08-18T11:45:07","modified_gmt":"2024-08-18T15:45:07","slug":"design-therapeutics-reports-positive-data-from-single-ascending-dose-trial-of-dt-216-for-the-treatment-of-friedreich-ataxia-and-portfolio-progress","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/design-therapeutics-reports-positive-data-from-single-ascending-dose-trial-of-dt-216-for-the-treatment-of-friedreich-ataxia-and-portfolio-progress.php","title":{"rendered":"Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress"},"content":{"rendered":"<p><![CDATA[DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia]]><\/p>\n<p>Read this article:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/12\/07\/2569704\/0\/en\/Design-Therapeutics-Reports-Positive-Data-from-Single-Ascending-Dose-Trial-of-DT-216-for-the-Treatment-of-Friedreich-Ataxia-and-Portfolio-Progress.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress\">Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read this article: Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/design-therapeutics-reports-positive-data-from-single-ascending-dose-trial-of-dt-216-for-the-treatment-of-friedreich-ataxia-and-portfolio-progress.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068265","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068265"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068265"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068265\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}